Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Repare Therapeutics Inc.

< Previous 1 2 3 Next >
Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Participate at the Goldman Sachs 43rd Annual Global Healthcare Conference
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Insiders Establish New and Modified Automatic Securities Disposition Plans
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Announces Closing of Upsized Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Announces Pricing of Upsized Offering of Common Shares
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Announces Proposed Public Offering of Common Shares
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Participate at the H.C. Wainwright 2nd Annual Precision Oncology Conference
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Presents Preliminary Phase 1 Monotherapy Clinical Data from the Ongoing First-in-Human Phase 1/2 TRESR Study of RP-3500 in Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Present Initial Data from the Phase 1/2 TRESR RP-3500 Clinical Trial at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Appoints Thomas Civik to Its Board and as New Chairman
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Participate at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics to Participate at the 42nd Annual Goldman Sachs Virtual Global Healthcare Conference
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
Repare Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Tickers RPTX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.